Restoring Lives
One Story At A Time

We are Assertio — an assertive, energetic, and empathetic pharmaceutical company built around the mission of advancing patient care. Formerly known as Depomed, we have transformed our company with a current focus on three FDA-approved products in our core areas of neurology, orphan, and specialty medicines, as we continue to identify, license, and develop new products that offer enhanced options for patients who may be underserved by existing therapies. More

In the News

January 13, 2020

Assertio Therapeutics Announces Closing of Gralise® Sale to Alvogen and Expects Full-Year 2019 Neurology Franchise Net Sales Above Upper End of Prior GuidanceRead More

December 12, 2019

Assertio Therapeutics Announces Sale of Gralise® for Total Transaction Value of $127.5 MillionRead More

November 26, 2019

Assertio Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare ConferenceRead More

More News